Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Daxor presented at the iAccess Alpha Virtual Best Ideas Spring Investment Conference highlighting its 20,000 sq ft Oak Ridge facility and capacity to produce up to 200,000 diagnostic test kits per year. The NASDAQ-listed company stressed its vertically integrated manufacturing of companion analyzers and Volumex, a radiopharmaceutical diagnostic injected to measure blood volume. Management framed the company's mission as enabling optimal blood volume management across the healthcare system.

Analysis

The most consequential, under-discussed variable is commercialization cadence: manufacturing capacity removes an early supply constraint, but adoption hinges on three payer/clinical inflection points — a favorable CMS coding/coverage decision, 1–2 peer-reviewed outcomes studies showing reduced length-of-stay/readmissions, and a handful of IDN pilot wins that create referral cascades. These events operate on a 6–24 month timeline and are non-linear; a single large IDN rollout can flip adoption curves quickly because radiopharma diagnostics sell through clinical pathways rather than commodity channels.

Second-order beneficiary pools extend beyond the company: hospital systems and value-based care managers stand to cut avoidable volume-driven costs if the test changes fluid-management protocols, while isotope producers and radiopharm contract manufacturers face upside from increased demand for labeled kits — creating opportunity for third-party tolling or licensing revenue if the company chooses to monetize excess capacity. Conversely, large imaging OEMs and legacy point-of-care fluid assessment vendors are at risk of losing marginal procedure share if clinicians prefer direct blood-volume quantification tied to outcomes.

Key risks are binary and timing-sensitive. Regulatory/reimbursement reversals, persistent clinician skepticism, or an Mo-99/Tc-99m supply disruption would materially delay revenues and compress multiple expansion, while a favorable national coverage decision or publication in a high-impact clinical journal could accelerate uptake and re-rate the stock within 3–12 months. Operational execution risk — channel build, shipping logistics for a radiopharmaceutical, and sales force effectiveness — is the primary near-term value lever and the quickest way the story can reverse.

The consensus under-appreciates optionality from non-core monetization: with in-house production scale, the firm can pivot to B2B supply, license labeled reagents, or pursue OEM partnerships that de-risk direct hospital sales. That latent business-model flexibility means early revenue disappointments need not be terminal; they create negotiation leverage with strategic partners who prefer an onshore, vertically integrated radiopharma supplier for clinical programs.

Key Decisions for Investors

• Long DXR (size 1–2% NAV) 12–24 month horizon — R/R asymmetric: downside capped by execution/regulatory risk, upside driven by 2–3 commercial/coverage catalysts; add conviction on any IDN rollout announcement or favorable CMS coding language.
• Hedge via protective puts rather than naked short: buy DXR 6–9 month protective puts sized to limit drawdown to ~30% of position cost to protect against binary regulatory or supply shocks (options liquidity risk acknowledged).
• Event-driven options: buy DXR LEAPS (12–24 month calls) to capture re-rate if a major peer-reviewed outcomes study or national coverage decision prints; prefer OTM strikes to keep premium capital efficient given current illiquidity.
• Pair trade for deployment-risk mitigation: long DXR / short GE (GE) small size — this hedges broad imaging capex cyclicality while keeping exposure to the radiopharma commercialization-specific upside (hold 12 months and re-evaluate on first IDN rollout).